Dai-ichi Life Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Dai-ichi Life Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-17,560	Closed	-$1.19M	–	26
2016 Q3	$1.19M	Buy	+17,560	New	+$1.24M	0.04%	385
2015 Q3	–	Sell	-1,688	Closed	-$202K	–	561
2015 Q2	$202K	Buy	+1,688	New	+$202K	0.01%	573
2014 Q2	–	Sell	-15,560	Closed	-$1.04M	–	641
2014 Q1	$1.04M	Buy	+15,560	New	+$1.2M	0.03%	382

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dai-ichi Life Holdings's ALNY Position: Q4 2016 in Review

Dai-ichi Life Holdings sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 17,560 shares — an estimated $1.19M sold.

Dai-ichi Life Holdings first reported a position in ALNY in Q1 2014 and held it in 3 quarters. The position peaked at $1.19M in Q3 2016. 210 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Dai-ichi Life Holdings reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Dai-ichi Life Holdings sold 17,560 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $1.19M.
Dai-ichi Life Holdings first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 3 quarters.
Dai-ichi Life Holdings's Alnylam Pharmaceuticals position peaked at $1.19M in Q3 2016.
210 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Dai-ichi Life Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.